socalTECH

MARCH 13, 2014

San Diego-based AnaptysBio , a biopharmaceuticals firm focused on the development of therapeutic antibodies, announced a deal today with TESARO. According to AnaptysBio, it will receive an upfront license fee of $17M from TESARO, plus receive funding of costs incurred in related development programs, as part of an antibody program.

Avalon 138

Avalon San Diego Venture Capital Research 138

socalTECH

AUGUST 4, 2014

San Diego-based Otonomy , which is developing treatments for diseases of the inner and middle ear, set its estimated IPO pricing range Friday. Otonomy has applied to list on the NASDAQ Global Market as OTIC. The company indicated in a filing that it now expects its IPO at between $14.00 and $16.00

Pricing 147

Pricing Avalon San Diego Acquisition 147

socalTECH

SEPTEMBER 1, 2009

San Diego-based Awarepoint , a developer of real-time location systems for the healthcare market, reported Monday that former Motorola CEO and Sun Microsystems President Ed Zander has joined its board. Awarepoint is developing RTLS systems based on the Zigbee wireless standard. READ MORE>>.

Avalon 133

Avalon San Diego Report Marketing 133

socalTECH

NOVEMBER 25, 2008

San Diego-based Awarepoint, a developer of systems for tracking assets and patients in hospitals, has raised $13.3M The firm said the round was led by Cardinal partners, and also included Venrock and prior investor Avalon Ventures. in a Series D funding. The firm offers its services as software-as-a-service to the healthcare industry.

Avalon 100

Avalon San Diego Funding Services 100

Xconomy

JANUARY 26, 2017

biotech company to go public this year, raising $75 million in an IPO intended to finance development of antibody-based drugs for inflammatory disorders. As has been the case for biotechs over the past year , insiders helped Anaptys get to the public market. AnaptysBio is the first U.S. Stockholders who had invested in the.

Marketing 40

Marketing San Diego Invest Help 40

Xconomy

SEPTEMBER 30, 2016

Who will be first to market with a new type of cancer treatment known as CAR-T? Who will break free of the pack of companies developing drugs meant to prevent migraines? —Sarepta inked a research pact with Catabasis Pharmaceuticals (NASDAQ: CATB ) to develop a combination therapy for Duchenne.

Avalon 40

Avalon Thousand Oaks Study Startup 40

Tech Zulu Event

DECEMBER 6, 2013

Auto-interfaces are clunky, and when a lot of these big tech companies IPO’d, a lot of them developed products that were endemic to the car industry – navigation, social graphs, etc. ” CHANGING THE FACE OF AUTOMOTIVE MARKETING. As they became adopted by millions, they leap-frogged us in terms of capability. .

Advertising 97

Advertising Startup Marketing Mobile 97

socalTECH

SEPTEMBER 19, 2008

We seem to receive lots of pitches from companies looking to attack the mobile market with their mobile software applications, but few who have deployed on-deck with carriers. in funding from Venrock, Avalon, and Masthead. Derrick Oien: We have a platform we develop, called ANTHEM. Intercasting is backed by $17.5M

Social Network 113

Social Network Anthem Mobile Java 113